Eric Hsu
Corporate Officer/Principal chez INMED PHARMACEUTICALS INC.
Fortune : 13 $ au 30/04/2024
Postes actifs de Eric Hsu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| INMED PHARMACEUTICALS INC. | Corporate Officer/Principal | 13/03/2018 | - |
Historique de carrière de Eric Hsu
Anciens postes connus de Eric Hsu
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Directeur des opérations | 01/01/2002 | 01/01/2018 |
| Directeur Technique/Scientifique/R&D | 01/01/2002 | 01/01/2018 |
Formation de Eric Hsu
| McGill University | Undergraduate Degree |
| University of Toronto | Doctorate Degree |
Statistiques
Internationale
| Canada | 5 |
Opérationnelle
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Health Technology |
